ClinicalTrials.gg
RecruitingNCT05794945OPTIMISTUpdated Mar 12, 2026

Optimizing Mastitis Identification and Treatment

An observational study in Mastitis Postpartum, sponsored by University of Tromso. Recruiting at 2 sites in Norway. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of Tromso · Observational

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The goal of this observational study is to gain more information about the aetiology and progression of mastitis and breast inflammation, in order to develop evidence-based clinical guidelines and treatment plans, especially concerning judicious use of antibiotics.

The main questions it aims to answer are:

  • Do clinical symptoms differ between inflammatory and infectious mastitis?
  • What is the microbial composition in human milk, and does it change before, during, and after episodes of mastitis?
  • Does the bacterial composition change due to antibiotic treatment?
  • Are all mastitis episodes treated with antibiotics bacterial mastitis?
  • Do mothers with recurrent mastitis have a distinct microbial composition?
  • Are there immunological markers that can differentiate between bacterial and inflammatory mastitis?

Researchers will compare breastfeeding women with and without mastitis to see if the microbiological composition in milk and on the skin of the breast and breast nipple differs.

Read the detailed description

Mastitis (breast inflammation) is experienced by up to one-fifth of all breastfeeding mothers. Mastitis is a painful condition and a leading cause of early weaning, an undesired outcome with potentially negative implications for both mother and baby. Empirical evidence explaining the aetiology of mastitis is lacking; thus the definitions and treatment of mastitis is conflicting. The recent mechanobiological model proposes that the mechanical forces of lactation, especially at the onset of milk production, can cause damage to the mammary tissue, which induces an inflammatory response. Concurrently a growing amount of evidence shows that bacteria previously written off as contaminants have a role in mastitis which has been overlooked. The dynamics between the mechanobiological model and bacterial colonization have not yet been investigated. To fill this knowledge gap, researchers will conduct a longitudinal study collecting milk samples and questionnaires during the breastfeeding period with a particular emphasis on mastitis. Milk and skin swab samples will be used for culture dependent and culture independent assessment of the microbial composition in mastitis, and will be compared to the composition found in mothers without mastitis.

The main objective of this clinical study is to gather empirical data to provide an evidence-based update to the clinical guidelines for mastitis diagnosis and care. This will provide a foundation for improving the treatment and prevention of mastitis, with better outcomes for mothers and newborns.

02

Conditions studied

  • Mastitis Postpartum

Browse trials for

Keywords

  • Breast inflammation
  • Clinical mastitis
  • Sub-clinical mastitis
03

In context

Mastitis

31 studies on the registry are indexed under Mastitis; 7 are open to participants now.

This study's planned enrollment of 300 is above the median of 211 across 14 observational studies indexed under Mastitis.

Browse Mastitis studies →

Lead sponsor

University of Tromso is the lead sponsor of 60 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant mothers aged > 18 years planning to give birth at University Hospital Noth Norway (UNN), with the intention to breastfeed and with an address in Tromsø municipality.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant mothers aged > 18
  • mothers must understand information given in Norwegian or English
  • participants must be willing to complete study questionnaires
  • participants must be willing to and provide biological samples

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Breastfeeding mothers

    In this study breastfeeding mothers will be included. Samples will be collected from breast-feeding mothers experiencing mastitis Samples will be collected from breast-feeding mothers after the mastitis episode is resolved Breastfeeding mothers will be sampled at each mastitis episode, and with the final sample collected after a maximum of 12 months

06

What researchers measure

Primary outcomes

  1. Determination of the microbial composition in human milk from mothers without mastitis by MALDTI-TOF and Illumina sequencing

    In order to investigate if there is a particular microbial composition of the human milk that leads to mastitis, the microbial composition in human milk from mothers without mastitis will be assessed. The investigators will collect milk samples from all enrolled mothers at day 6-7 after birth. Milk samples will be stored at -20 until further processing. Mothers who develop mastitis will be further sampled as described in outcome 2. Samples will be analyzed using culture dependent and culture independent methods. Following culturing of the milk samples, colonies will be analysed by Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) to identify bacterial species. DNA will be isolated from the same milk sample.16S rRNA amplicon sequencing of DNA from milk samples will be performed using the Illumina technology, in order to get an overview of the total bacterial composition.

    Time frame: 18 months

  2. Determination of the microbial composition in human milk from mothers at onset of mastitis by MALDTI-TOF and Illumina sequencing

    The investigators will investigate if the microbial composition in human milk changes at onset of mastitis. By analysing possible changes in microbial composition the investigators will assess if the mastitis symptoms are caused by microorganisms, or if the symptoms of mastitis are inflammatory. Milk samples will be collected by the mother at onset of mastitis, 24 hours after onset of symptoms and after resolution of symptoms. If the mastitis episode is treated with antibiotics, a new sample will be taken 24 hours after cessation of antibiotic treatment. Milk samples will be stored at -20 until further processing. Samples will be analyzed using culture dependent, and culture independent methods. Following culturing of the samples, colonies will be analysed by MALDI-TOF to identify bacterial species. 16S rRNA amplicon sequencing of DNA from milk samples will be performed using the Illumina technology, in order to get an overview of the total bacterial composition.

    Time frame: 18 months

  3. Assessment of the microbial composition on nipples of mothers without mastitis

    It is no agreement on if mastitis causing bacteria originate from the breast nipple, or if they are part of the milk microbiome. We will sample the breast nipples in order to investigate if microorganisms colonizing the breast skin enter the mammary glands, and potentially cause mastitis. A skin swab of the nipple (both breasts) will be taken at day 6-7 after birth. Following culturing of the swab, bacterial colonies will be analysed by MALDI-TOF to identify bacterial species. The skin swabs will be collected at the same timepoints as collection of milk samples.

    Time frame: 18 months

  4. Assessment of the microbial composition on nipples of mothers with mastitis

    It is no agreement on if mastitis causing bacteria originate from breast nipple, or if they are part of the milk microbiome. We will sample the breast nipples in order to investigate if microorganisms colonizing the breast skin enter the mammary glands, and potentially cause mastitis. When the mother experiences symptoms of mastitis the mother will collect a skin swab sample. Following culturing of the swab, bacterial colonies will be analysed by MALDI-TOF to identify bacterial species. The skin swabs will be collected at the same timepoints as collection of milk samples.The microbial composition on nipples of mothers with mastitis will also be compared to the nipple microflora of mothers without mastitis in order to see if there is a correlation between particular skin colonizing bacteria that cause mastitis.

    Time frame: 18 months

  5. The concentration of immunological markers in milk from mothers without mastitis

    A milk sample will be collected at day 6-7 after birth, and the concentration of immunological markers will be assessed in the milk of mothers without mastitis. The concentration (pg/ml) of 8 immune factors, including innate immune factors (IL6, IFNγ, TNFα), acquired immune factors (IL2, IL4, IL10), chemokines (IL8), and growth factor (GMCSF), will be determined by magnetic bead-based multi- plex immunoassays, using a Bioplex 200 instrument (Bio-Rad, Hercules, CA, USA).

    Time frame: 18 months

  6. The concentration of immunological markers in milk from mothers with mastitis

    In order to determine if there is an increase in the immunological markers present in milk from mothers with mastitis, milk samples will be collected at onset of mastitis symptoms and 24 hours after cessation of symptoms. If the mother requires antibiotic treatment , samples will be collected at onset of treatment and 24 hours after cessation of antibiotic treatment. The concentration (pg/ml) of 8 immune factors, including innate immune factors (IL6, IFNγ, TNFα), acquired immune factors (IL2, IL4, IL10), chemokines (IL8), and growth factor (GMCSF), will be determined by magnetic bead-based multi- plex immunoassays, using a Bioplex 200 instrument (Bio-Rad, Hercules, CA, USA).The investigators will assess if the concentration of immunological markers differs in bacterial mastitis and inflammatory mastitis.

    Time frame: 18 months

  7. Mapping of mastitis symptoms by detailed Questionnaires

    The mothers will be asked to fill in a detailed questionnaire regarding breastfeeding practice and symptoms of mastitis. The questionnaire will accompany the collection of milk samples as described in outcome 1and 2.

    Time frame: 18 months

07

Study locations

2 of 2 sites recruiting
  • Tromsø municipality, health centre
    Tromsø, Troms 9019, Norway
    Recruiting
  • UiT-The Arctic University of Norway
    Tromsø, 9019, Norway
    Recruiting
    • Pauline Cavanagh, PhD · Contactpauline.cavanagh@uit.no
    • Beate Fossum Løland, MD,PhD · Sub investigator
    • Ina Landau Aasen, MAc · Sub investigator
    • Hermoine Venter, PhD · Sub investigator
    • Claus Klingenberg, MD,PhD · Sub investigator
08

References and documents

Publications

  • Wilson E, Woodd SL, Benova L. Incidence of and Risk Factors for Lactational Mastitis: A Systematic Review. J Hum Lact. 2020 Nov;36(4):673-686. doi: 10.1177/0890334420907898. Epub 2020 Apr 14. PubMed 32286139 ↗
  • Mitchell KB, Johnson HM, Rodriguez JM, Eglash A, Scherzinger C, Zakarija-Grkovic I, Cash KW, Berens P, Miller B; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, Revised 2022. Breastfeed Med. 2022 May;17(5):360-376. doi: 10.1089/bfm.2022.29207.kbm. PubMed 35576513 ↗
  • Grzeskowiak LE, Saha MR, Ingman WV, Nordeng H, Ystrom E, Amir LH. Incidence, antibiotic treatment and outcomes of lactational mastitis: Findings from The Norwegian Mother, Father and Child Cohort Study (MoBa). Paediatr Perinat Epidemiol. 2022 Mar;36(2):254-263. doi: 10.1111/ppe.12824. Epub 2021 Nov 28. PubMed 34841537 ↗
  • Castro I, Garcia-Carral C, Furst A, Khwajazada S, Garcia J, Arroyo R, Ruiz L, Rodriguez JM, Bode L, Fernandez L. Interactions between human milk oligosaccharides, microbiota and immune factors in milk of women with and without mastitis. Sci Rep. 2022 Jan 25;12(1):1367. doi: 10.1038/s41598-022-05250-7. PubMed 35079053 ↗

Individual participant data

Plan to share: Yes — Researchers will share questionnaires, Informed consent forms and protocol, after data is published.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available after publication

Access criteria: Access upon request

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05794945
Lead sponsor
University of Tromso
Collaborators
Norwegian Institute of Public Health, The University of Western Australia, Helse Nord
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Oct 1, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Mar 12, 2026

Study contacts

Jorunn Pauline Cavanagh, PhD
Contact
pauline.cavanagh@uit.no
40498490 ext. 47
Claus Klingenberg, MD, PhD
Contact
claus.klingengerg@unn.no
91563167 ext. 47
Jorunn Pauline Cavanagh, PhD
principal investigator · The Arctic university of Norway-UiT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion